Overview of Dr. Galsky

Dr. Matthew Galsky is an oncologist in New York, NY and is affiliated with The Mount Sinai Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice 19 years. Dr. Galsky accepts several types of health insurance, listed below. He is one of 193 doctors at The Mount Sinai Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

• Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004

• Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1998 - 2001

• Tufts University School of MedicineClass of 1998

Certifications & Licensure

Clinical Trials

Publications & Presentations

PubMed

• Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma.

  Berg, S., Galsky, M.> ;Journal of Clinical Oncology. 2024 Feb 15

• Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-target...

  Chakrani, Z., Saffran, N., McCroskery, S., Taylor, N., Patel, M., Mellgard, G., Liaw, B., Galsky, M., Oh, W., Tsao, C., Patel, V.> ;American Journal of Clinical Oncology. 2024 Feb 12

• Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel.

  Myers, A., Kilbert, A., Kamat, A., Galsky, M.> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
• Join now to see all

Journal Articles

• Identification of microR-106b as a Prognostic Biomarker of p53-like Bladder Cancers by ActMiR  

  Matthew D Galsky, William K Oh, Nature

Lectures

• A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in ... 

  2019 ASCO Annual Meeting - 6/1/2019

• Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (m... 

  2019 ASCO Annual Meeting - 6/1/2019

• Is there a difference in PD-1 / PD-L1 inhibitors for urothelial cancer? Continuous Evolution of a Phase I Trial Into An FDA Package 

  2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

• Immunotherapy After Surgery Is Beneficial for High-Risk Bladder Cancer PatientsApril 3rd, 2023

• CheckMate 274 Follow up Data Boost Nivolumab Potential for High-Risk Bladder CancerMarch 8th, 2023

• CheckMate 274: Continued Disease-Free Survival Benefits with Adjuvant Nivolumab in High-Risk Urothelial CarcinomaMarch 8th, 2023

• Join now to see all

Hospital Affiliations

Insurance Accepted

• Aetna Choice POS II
  Aetna HMO
  BCBS Blue Card PPO
  CIGNA HMO
  CIGNA Open Access
  CIGNA PPO
  Empire BCBS HMO
  Empire BCBS PPO
  First Health PPO
  GHI PPO
  Great West PPO
  

  HIP of New York - Select PPO
  Humana ChoiceCare Network PPO
  MagnaCare PPO
  Multiplan PHCS PPO
  Multiplan PPO
  MVP Healthcare PPO
  Oxford Health Freedom
  Oxford Health Liberty
  United Healthcare - Direct Choice Plus POS
  United Healthcare - Direct Options PPO
  

• Please verify your coverage with the provider's office directly when scheduling an appointment